Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) Stock higher 17.99% in This Year: What’s Happened?

Oppenheimer raised the price target for the Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) stock to “an Outperform”. The rating was released on March 05, 2024, according to finviz. We previously noted in another research note published on March 05, 2024 by Needham that reiterated the stock to a Buy with a price target of $22 for AVDL stock. The research report from H.C. Wainwright has reiterated the stock to Buy, with a price target set at $25. The stock was initiated by UBS, who disclosed in a research note on February 06, 2024, to Buy and set the price objective to $21. In their research brief published November 30, 2022, Jefferies analysts upgraded the Avadel Pharmaceuticals plc ADR stock from Hold to Buy with a price target of $11.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -3.25% within the last five trades and 30.36% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 59.58% in the last 6 months and 14.19% was added to its value over the previous 3 months. AVDL stock is trading at a margin of 3.02%, 11.99% and 24.21% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


As of the close of trading, AVDL deals in the Healthcare domain. The stock is trading -4.64 percent below its 52-week high and 108.25 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 60.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Avadel Pharmaceuticals plc ADR’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -492.97 percent and the profit margin is -573.17 percent, and the company has reported a gross margin of 96.97 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $1.50 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 21.45. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 53.53 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 18.05, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 6.89 percent of Avadel Pharmaceuticals plc ADR shares are owned by insiders, and 56.21 percent are held by financial institutions. MCHUGH THOMAS S, the Chief Financial Officer at Avadel Pharmaceuticals plc ADR (AVDL) has bought 2,000 shares of firm on Jan 16 ’24 at a price of $14.50 against the total amount of $29000.0. In another inside trade, McCamish Mark Anthony, Director of Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) sold 75,000 shares of the firm on Dec 28 ’23 for a total worth of $1.09 million at a price of $14.53. An inside trade which took place on Aug 14 ’23, Chief Financial Officer of Avadel Pharmaceuticals plc ADR MCHUGH THOMAS S bought 2,000 shares of firm against total price of $28900.0 at the cost of $14.45 per share.

Most Popular

Related Posts